What HighCape Partners does

HighCape Partners (also operating as HighCape Capital) is a private growth equity fund founded in 2013 and headquartered at 36 Church Lane, Westport, Connecticut. The firm is purpose-built to invest in life sciences companies commercializing high-margin products across three sub-verticals: Connected Health, Medical Device/Tool, and Biotechnology. The team comprises four partners (co-founders Kevin Rakin and Matt Zuga, plus Jennifer Barretta and Dean Tozer) and three operating partners (Dr. Ranjit Bindra, Dr. Charles Hart, and Dr. Carol Reed), all of whom have at least 25 years of life sciences operating or investing experience, including repeated execution of founder-led life sciences companies through acquisition or IPO.

The fund generates returns through capital appreciation and successful exits of portfolio companies rather than product or service pricing. Its current disclosed portfolio includes five companies: Elutia (drug-eluting biomaterial platforms), Quantum-Si Incorporated (Nasdaq-listed chip-based proteomics), Wellinks (connected respiratory devices including the FDA-cleared Flyp nebulizer), Cybrexa Therapeutics (oncology intracellular drug delivery), and Alphina Therapeutics (NAD metabolism cancer therapeutics, IP licensed from Yale). Notable realized exits include Cheetah Medical (acquired by Baxter International, 2019), TELA Bio (IPO November 2019), ZipLine Medical (acquired by Stryker, December 2019), and Modifi Biosciences (acquired by Merck, 2024).

The fund differentiates through a hands-on operating model in which partners and operating partners take active roles alongside portfolio company management teams in commercial strategy, HR/leadership development, and scientific direction. Distribution is conducted through a corporate website (highcape.com) and an LP portal for limited partner access. A $1.43M capital close was recorded on July 24, 2025, with investors not publicly disclosed. Geographic footprint is primarily U.S., though board exposure includes European-listed Nyxoah SA, suggesting selective cross-border activity.

Name

HighCape Partners

Legal name

HighCape Capital

Website

https://highcape.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

HighCape Partners is a 2013-vintage Westport, CT-based private growth equity fund investing in life sciences companies commercializing high-margin products across Connected Health, Medical Device/Tool, and Biotechnology, serving portfolio management teams and undisclosed limited partners.

Ownership category

akta.pro rank

Product category

Growth Equity / Private Equity (Life Sciences)

NAICS

Portfolio Management and Investment Advice (523940), Investment Banking and Securities Intermediation (523150)

SIC

Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Growth equity fund
• Life sciences investment
• Biotechnology investment
• Medical device investing
• Healthcare venture capital

Headquarters

HQ city

Baltimore

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Distribution channels1 record

Marketing channels1 record

Core offering

HighCape Partners (d/b/a HighCape Capital) is a private growth equity fund created in 2013 that invests in Life Sciences companies across three verticals — Connected Health, Medical Device/Tool, and Biotechnology — providing growth capital alongside hands-on operational, commercial, and leadership support to help portfolio companies transition from early-stage businesses into thriving organizations.

Product overview

HighCape Partners is a growth equity fund focused exclusively on Life Sciences companies. Rather than offering a unified software product, the firm provides investment and operational support to its portfolio companies across three investment areas: Connected Health, Medical Device/Tool, and Biotechnology. The portfolio includes Elutia (drug-eluting biomaterials), Quantum-Si (chip-based proteomics tools), Wellinks (connected respiratory devices), Cybrexa Therapeutics (oncology drug delivery platform), and Alphina Therapeutics (NAD metabolism cancer therapeutics).

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• OrbiMed: One of the largest dedicated healthcare and life sciences investment firms globally, investing across venture, growth, and public equities. Comparable to HighCape as a sector-focused growth equity investor in life sciences, but at materially greater scale.
• HealthCare Royalty Partners: Healthcare-focused investment firm that provides capital to life sciences companies through royalty and structured equity transactions. Comparable in sector focus but operates with a differentiated financing model.
• Deerfield Management: Large healthcare investment firm with venture, growth, and public market strategies across the life sciences value chain. Comparable to HighCape in life sciences focus but with substantially broader mandate and scale.

Direct peers

• Versant Ventures: Healthcare-focused venture and growth equity firm investing in biotechnology, medical devices, and healthcare services. Directly comparable to HighCape in its life sciences vertical specialization and operating-partner model.
• Longitude Capital: Growth equity firm focused on life sciences and healthcare, with investments in biotechnology, medical devices, and connected health. Highly comparable to HighCape in fund size, sector focus, and growth-stage investing approach.
• New Leaf Venture Partners: Healthcare-focused growth equity firm investing in late-stage life sciences companies. Closely comparable to HighCape in mandate, fund size, and hands-on operating support to portfolio companies.
• SV Health Investors: Healthcare and life sciences growth and venture investment firm with deep sector specialization and an operating-partner model similar to HighCape. Directly comparable in biotech, medical device, and connected health focus.
• 5AM Ventures: Early-stage life sciences venture firm with a focus on biotech and platform technologies emerging from academic institutions. Comparable to HighCape in its reliance on academic spinouts and concentrated life sciences mandate.
• Atlas Venture: Early-stage biotech-focused venture firm that builds and funds companies around academic science, similar to HighCape's Yale-driven deal flow. Overlaps in life sciences vertical specialization though typically at earlier stages.
• Clarus Ventures: Healthcare and life sciences-focused venture and growth equity firm with operating-partner involvement in portfolio companies. Directly comparable to HighCape in sector focus and investment approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments20 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HighCape Partners